Geron Corp Stock Price, News & Analysis

Geron Corporation (GERN) has granted equity awards totaling 1,116,000 shares to 16 new employees as employment inducement. The grants include 744,000 stock options priced at $1.45 per share with a 10-year term, vesting over 4 years with 12.5% vesting at 6 months and the remainder over 42 months. Additionally, 372,000 RSUs were awarded, vesting 25% annually over 4 years. The awards were granted on June 17, 2025, by Geron's Compensation Committee under Nasdaq Rule 5635(c)(4) and are subject to the company's 2018 Inducement Award Plan terms.

Geron Corporation (GERN) announced new presentations at ASCO and EHA 2025 highlighting RYTELO® (imetelstat) efficacy and safety data. New post-hoc analyses from the IMerge trial demonstrate clinical benefits in lower-risk myelodysplastic syndromes (LR-MDS) patients, regardless of ring sideroblast status, baseline serum erythropoietin levels, or prior therapy use. The data shows RYTELO's effectiveness in achieving transfusion independence across various patient subgroups. Updates on the IMpactMF trial revealed ~80% enrollment completion as of February 2025. The IMproveMF trial, studying imetelstat combined with ruxolitinib, showed promising preliminary results with good tolerability and encouraging dose-dependent efficacy data. Patient-centric outcomes demonstrated sustained quality-of-life improvements and longer duration without transfusion reliance compared to placebo.

Geron Corporation (GERN) has granted equity awards totaling 411,000 shares to six new employees as employment inducement. The awards, granted on May 16, 2025, consist of:

- Stock options to purchase 274,000 shares at $1.27 per share (closing price on grant date), with a 10-year term and 4-year vesting schedule

- Restricted Stock Units (RSUs) representing 137,000 shares, vesting 25% annually over 4 years

The grants were approved by Geron's Compensation Committee under Nasdaq Rule 5635(c)(4) and are subject to the company's 2018 Inducement Award Plan terms.

Geron Corporation (GERN) reported Q1 2025 financial results, with RYTELO® net product revenue of $39.4M, down from $47.5M in Q4 2024 due to inventory drawdown. The company posted a net loss of $19.8M ($0.03 per share), improved from $55.4M loss in Q1 2024. Key highlights include: European Commission marketing authorization for RYTELO for lower-risk MDS treatment, with EU launch planned for 2026; approximately 85% enrollment in Phase 3 IMpactMF trial for myelofibrosis, with interim analysis expected in 2H 2026. Cash position stands at $457.5M as of March 31, 2025. Operating expenses were $56.3M, with the company maintaining its 2025 guidance of $270-285M in total operating expenses.

Geron (Nasdaq: GERN) has granted equity awards totaling 1,551,000 shares to twelve new employees as employment inducement. The grants, issued on April 17, 2025, include:

• 1,034,000 shares as stock options with $1.27 per share exercise price
• 517,000 shares as restricted stock units (RSUs)

The stock options have a 10-year term with a vesting schedule of 12.5% after six months and the remaining over 42 months. RSUs vest 25% annually over four years. These awards were approved by Geron's Compensation Committee under Nasdaq Rule 5635(c)(4) and are subject to the company's 2018 Inducement Award Plan.

Geron (GERN) has scheduled the release of its first quarter 2025 financial results before market opening on Wednesday, May 7, 2025. The company will distribute the results via press release, which will be accessible on their investor relations website.

Following the release, Geron will host a conference call at 8:00 a.m. Eastern Time to discuss financial performance and business highlights. Investors can access a live webcast of the conference call and accompanying presentation through the company's website, with the recording remaining available for 30 days afterward.

Geron (Nasdaq: GERN) has announced the granting of equity awards to three newly hired employees as inducement for their employment. The awards, granted on March 17, 2025, consist of:

• 150,000 shares in stock options with an exercise price of $1.74 per share
• 75,000 shares in restricted stock units (RSUs)

The stock options have a 10-year term with a vesting schedule of 12.5% after six months and the remaining shares vesting over 42 months. RSUs vest 25% annually over four years. These awards were granted under Geron's 2018 Inducement Award Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Geron (GERN) has received European Commission (EC) approval for RYTELO® (imetelstat), the first-in-class telomerase inhibitor for treating adults with transfusion-dependent anemia due to lower-risk MDS (LR-MDS). The approval applies to patients without del-5q abnormality who are either ineligible for or had unsatisfactory response to erythropoietin-based therapy.

The approval is based on the IMerge Phase 3 clinical trial results, which showed significant reduction in red blood cell transfusion dependency during the first 24 weeks compared to placebo. The most common adverse reactions included neutropenia (69%) and thrombocytopenia (63%), typically resolving within four weeks.

RYTELO's marketing authorization covers all 27 EU member states, Iceland, Norway, and Liechtenstein. Geron plans to commercialize RYTELO in select EU countries starting in 2026, pending reimbursement approvals. The drug maintains orphan drug designation, providing 10-year market exclusivity, with patent exclusivity anticipated until 2038.

Geron (Nasdaq: GERN) announced significant leadership changes, with CEO John 'Chip' A. Scarlett set to depart on March 31, 2025. Board member Dawn Carter Bir has been appointed as Interim President and CEO, effective immediately, while Elizabeth G. O'Farrell becomes Chair of the Board.

The company, which recently achieved FDA approval for its first commercial product RYTELO® (imetelstat) for treating certain patients with lower-risk MDS, is now searching for a new CEO with substantial commercial experience. Under Scarlett's 14-year leadership, Geron also advanced a potential second indication for treating JAK inhibitor relapsed/refractory myelofibrosis into a Phase 3 registrational trial.